Neurologic Aspects of Drug Abuse

Neurologic Clinics

Volumn 28, Issue 1, 2010, Pages 199-215

  Goforth, Harold W ^a,b   Murtaugh, Reed ^c   Fernandez, Francisco ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Addiction; Epidemiology; Neurobiology; Neurotoxicity

Indexed keywords

ACAMPROSATE; ALCOHOL; AMFEBUTAMONE; AMPHETAMINE; ANTIDEPRESSANT AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CANNABIS; CENTRAL STIMULANT AGENT; CLONIDINE; COCAINE; DEPADE; DIAMORPHINE; DISULFIRAM; DOPAMINE RECEPTOR STIMULATING AGENT; LYSERGIDE; METHADONE; METHAMPHETAMINE; MIRTAZAPINE; NALTREXONE; NICOTINE; ONDANSETRON; OPIATE; PHENCYCLIDINE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SOLVENT; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALCOHOL ABUSE; ALCOHOL INTOXICATION; ALCOHOL WITHDRAWAL; ALCOHOLISM; CANNABIS ADDICTION; CLINICAL TRIAL; COCAINE DEPENDENCE; DETOXIFICATION; DRUG ABUSE; DRUG DEPENDENCE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEROIN DEPENDENCE; HUMAN; NAUSEA; NEUROLOGIC DISEASE; NEUROTOXICITY; OPIATE ADDICTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SECOND MESSENGER; TERATOGENICITY; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

ANIMALS; BRAIN; HUMANS; NERVOUS SYSTEM DISEASES; SUBSTANCE-RELATED DISORDERS;

EID: 70449643285     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2009.09.010     Document Type: Review

References (60)

1. Sampson P.D., Streissguth A.P., Bookstein F.L., et al. Incidence of fetal alcohol syndrome and prevalence of alcohol-related neurodevelopmental disorder. Teratology 56 5 (1997) 317-326
2. Stratton K.R., Howe C.J., and Battaglia F.C. Fetal alcohol syndrome: diagnosis, epidemiology, prevention, and treatment (1996), National Academy Press, Washington, DC
3. Sokol R.J., Delaney-Black V., and Nordstrom B. Fetal alcohol spectrum disorder. JAMA 290 22 (2003) 2996-2999
4. Carlen P.L., McAndrews M.P., Weiss R.T., et al. Alcohol-related dementia in the institutionalized elderly. Alcohol Clin Exp Res 18 6 (1994) 1330-1334
5. Torvik A. Wernicke's encephalopathy-prevalence and clinical spectrum. Alcohol Alcohol Suppl 1 (1991) 381-384
6. Hingson R.W., Zha W., and Weitzman E.R. Magnitude of and trends in alcohol-related mortality and morbidity among U.S. college students ages 18-24, 1998-2005. J Stud Alcohol Drugs Suppl 16 (2009) 12-20
7. Nida. Nida epidemiologic trends in drug abuse. In: proceedings of the Community Epidemiology Work Group: highlights and executive summary, U.S.D.o.H.a.H. Service, editor. 2008. National Institutes of Health.
8. Kliegman R.M., Madurra D., Kiwi R., et al. Relation of maternal cocaine use to the risks of prematurity and low birth weight. J Pediatr 124 5 Pt 1 (1994) 751-756
9. Singer L., Arendt R., Song L.Y., et al. Direct and indirect interactions of cocaine with childbirth outcomes. Arch Pediatr Adolesc Med 148 9 (1994) 959-964
10. Qureshi A.I., Suri M.F., Guterman L.R., et al. Cocaine use and the likelihood of nonfatal myocardial infarction and stroke: data from the Third National Health and Nutrition Examination Survey. Circulation 103 4 (2001) 502-506
11. Westover A.N., McBride S., and Haley R.W. Stroke in young adults who abuse amphetamines or cocaine: a population-based study of hospitalized patients. Arch Gen Psychiatry 64 4 (2007) 495-502
12. Nanda A., Vannemreddy P., Willis B., et al. Stroke in the young: relationship of active cocaine use with stroke mechanism and outcome. Acta Neurochir Suppl 96 (2006) 91-96
13. Association A.P. Diagnostic and statistical manual of mental disorders. 4th edition (2000), American Psychiatic Association, Washington, DC
14. Angrist B., Sathananthan G., Wilk S., et al. Amphetamine psychosis: behavioral and biochemical aspects. J Psychiatr Res 11 (1974) 13-23
15. Fitzgerald J.L., and Reid J.J. Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices. Eur J Pharmacol 191 2 (1990) 217-220
16. Snyder S.H. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry 133 2 (1976) 197-202
17. Kollins S.H., MacDonald E.K., and Rush C.R. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav 68 3 (2001) 611-627
18. Gaoni Y., and Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 86 8 (2002) 1646-1647
19. Martin B.R., and Wiley J.L. Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain. J Support Oncol 2 4 (2004) 305-314 [discussion: 314-6]
20. Adams I.B., and Martin B.R. Cannabis: pharmacology and toxicology in animals and humans. Addiction 91 11 (1996) 1585-1614
21. Gold M.S., Miller N.S., and Jonas J.M. Cocaine (and crack): neurobiology. In: Lowinson J.H., Ruiz P., and Millman R.B. (Eds). Substance abuse: a comprehensive textbook (1992), Williams & Wilkins, Baltimore (MD)
22. Tabakoff B., and Hoffman P.L. Alcohol: neurobiology. In: Lowinson J.H., Ruiz P., and Millman R.B. (Eds). Substance abuse: a comprehensive textbook (1992), Williams & Wilkins, Baltimore (MD)
23. Ungerleider T.J., and Pechnick R.N. Hallucinogens. In: Lowinson J.H., Ruiz P., and Millman R.B. (Eds). Substance abuse: a comprehensive textbook (1992), Williams & Wilkins, Baltimore (MD)
24. Balfour D.J. The effects of nicotine on brain neurotransmitter systems. Pharmacol Ther 16 2 (1982) 269-282
25. Lipman A.J., and Jackson K.C. Opioid pharmacotherapy. In: Warfield C., and Bajwa Z. (Eds). Principles and practice of pain medicine (2004), McGraw Hill Publishers, New York 583-600
26. Zukin S.R., and Zukin R.S. Phencyclidine. In: Lowinson L.H., Ruiz P., and Millman R.B. (Eds). Substance abuse: a comprehensive textbook (1992), Williams & Wilkins, Baltimore (MD)
27. Flanagan R.J., Ruprah M., Meredith T.J., et al. An introduction to the clinical toxicology of volatile substances. Drug Saf 5 5 (1990) 359-383
28. Koob G.F., Kenneth Lloyd G., and Mason B.J. Development of pharmacotherapies for drug addiction: a Rosetta stone approach. Nat Rev Drug Discov 8 6 (2009) 500-515
29. Kalivas P.W., and McFarland K. Brain circuitry and the reinstatement of cocaine-seeking behavior. Psychopharmacology (Berl) 168 1-2 (2003) 44-56
30. Nestler E.J. Molecular neurobiology of addiction. Am J Addict 10 3 (2001) 201-217
31. De Witte P., Littleton J., Parot P., et al. Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs 19 6 (2005) 517-537
32. Swift R. Emerging approaches to managing alcohol dependence. Am J Health Syst Pharm 64 5 Suppl 3 (2007) S12-S22
33. Fuller R.K., Branchey L., Brightwell D.R., et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 256 11 (1986) 1449-1455
34. Anton R.F. Naltrexone for the management of alcohol dependence. N Engl J Med 359 7 (2008) 715-721
35. Garbutt J.C., Kranzler H.R., O'Malley S.S., et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 293 13 (2005) 1617-1625
36. Mason B.J. Acamprosate for alcohol dependence: an update for the clinician. Focus 4 4 (2006) 505-511
37. Anton R.F., O'Malley S.S., Ciraulo D.A., et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295 17 (2006) 2003-2017
38. Besson J., Aeby F., Kasas A., et al. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 22 3 (1998) 573-579
39. George D.T., Rawlings R., Eckardt M.J., et al. Buspirone treatment of alcoholism: age of onset, and cerebrospinal fluid 5-hydroxyindolacetic acid and homovanillic acid concentrations, but not medication treatment, predict return to drinking. Alcohol Clin Exp Res 23 2 (1999) 272-278
40. Lejoyeux M. Use of serotonin (5-hydroxytryptamine) reuptake inhibitors in the treatment of alcoholism. Alcohol Alcohol Suppl 1 (1996) 69-75
41. Johnson B.A., Ait-Daoud N., and Prihoda T.J. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence. Alcohol Clin Exp Res 24 5 (2000) 737-742
42. Sellers E.M., Toneatto T., Romach M.K., et al. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 18 4 (1994) 879-885
43. Johnson B.A., Rosenthal N., Capece J.A., et al. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med 168 11 (2008) 1188-1199
44. Heroin Abuse and Addiction. National Institute on Drug Abuse, U.S. Department of Health and Human Services (2000), National Institutes of Health, Rockville (MD)
45. Kosten T.R., Schottenfeld R., Ziedonis D., et al. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis 181 6 (1993) 358-364
46. Barnett P.G., Rodgers J.H., and Bloch D.A. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 96 5 (2001) 683-690
47. Mattick R.P., Kimber J., Breen C., et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2 (2003) CD002207
48. Kleber H.D., Riordan C.E., Rounsaville B., et al. Clonidine in outpatient detoxification from methadone maintenance. Arch Gen Psychiatry 42 4 (1985) 391-394
49. Gold M.S., Redmond Jr. D.E., and Kleber H.D. Clonidine in opiate withdrawal. Lancet 1 8070 (1978) 929-930
50. O'Connor P.G., Carroll K.M., Shi J.M., et al. Three methods of opioid detoxification in a primary care setting. A randomized trial. Ann Intern Med 127 7 (1997) 526-530
51. Kosten T. Pathophysiology and treatment of cocaine dependence, the fifth generation of progress. In: Davis K.L., Charney D.S., Coyle J.T., et al. (Eds). Neuropsychopharmacology (2002), Lippincott, Williams & Wilkins, Baltimore (MD) 1461-1475
52. Grabowski J., Rhoades H., Schmitz J., et al. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol 21 5 (2001) 522-526
53. Grabowski J., Roache J.D., Schmitz J.M., et al. Replacement medication for cocaine dependence: methylphenidate. J Clin Psychopharmacol 17 6 (1997) 485-488
54. Anderson A.L., Reid M.S., Li S.H., et al. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend 104 1-2 (2009) 133-139
55. Carroll K.M., Fenton L.R., Ball S.A., et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry 61 3 (2004) 264-272
56. Elkashef A.M., Rawson R.A., Anderson A.L., et al. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 33 5 (2008) 1162-1170
57. Reichel C.M., Murray J.E., Grant K.M., et al. Bupropion attenuates methamphetamine self-administration in adult male rats. Drug Alcohol Depend 100 1-2 (2009) 54-62
58. Kongsakon R., Papadopoulos K.I., and Saguansiritham R. Mirtazapine in amphetamine detoxification: a placebo-controlled pilot study. Int Clin Psychopharmacol 20 5 (2005) 253-256
59. Newton T.F., Reid M.S., De La Garza R., et al. Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. Int J Neuropsychopharmacol 11 8 (2008) 1037-1045
60. 2 partial agonist aripiprazole (Abilify). Exp Clin Psychopharmacol 16 6 (2008) 475-483